Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 7/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL47301 | 0.92 | TGFBR1 (0.52) | CTSKCTSSTGFBR1PPARAPPARG | |
| SCHEMBL315980 | 0.92 | TGFBR1 (0.52) | CTSKCTSSTGFBR1PPARAPPARG | |
| SCHEMBL47290 | 0.92 | TGFBR1 (0.52) | CTSKCTSSTGFBR1PPARAPPARG | |
| Water SCHEMBL23833041 | 0.90 | CTSS (0.54) | CTSKCTSSTGFBR1PPARAPPARG | |
| Water SCHEMBL31557653 | 0.90 | CTSS (0.54) | CTSKCTSSTGFBR1PPARAPPARG | |
| Ammonia Solution, Strong SCHEMBL28315164 | 0.90 | CTSK (0.50) | CTSKCTSSTGFBR1PPARAPPARG | |
| SCHEMBL15886981 | 0.83 | CTSK (0.44) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL2728681 | 0.82 | CTSK (0.47) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL212772 | 0.82 | CTSK (0.47) | CTSKCTSSPPARAPPARGCTSL | |
| SCHEMBL212773 | 0.82 | CTSK (0.47) | CTSKCTSSPPARAPPARGCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10150794-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2018-12-11 | — | — | US | disclosed |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2017-09-14 | — | — | US | disclosed |
| EP-2623113-B1 | Compound for enzyme inhibition | ONYX THERAPEUTICS INC (US) | 2017-05-31 | — | — | EP | disclosed |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2016-03-24 | — | — | US | disclosed |
| US-9205124-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205126-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9205125-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-8716322-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20140050737-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140051641-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140031297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| EP-2623113-A2 | Compounds For Enzyme Inhibition | Onyx Therapeutics, Inc. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ONYX THERAPEUTICS, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-7687456-B2 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | PROTEOLIX, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2008140782-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| EP-1948678-A1 | COMPOUNDS FOR ENZYME INHIBITION | Proteolix, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007056464-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130130968-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | CTSK 227/4885CTSS 177/4885TGFBR1 4191/4885 |
| US-20070105786-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, PSMB1, PSMB3 | CTSK 171/4885CTSS 125/4885TGFBR1 3753/4885 |
| US-20170260230-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | CTSK 205/4885CTSS 88/4885TGFBR1 3761/4885 |
| US-20140050737-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | CTSK 227/4885CTSS 177/4885TGFBR1 4191/4885 |
| US-20140051641-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | CTSK 227/4885CTSS 177/4885TGFBR1 4191/4885 |
| US-20140031297-A1 | COMPOUNDS FOR ENZYME INHIBITION | ANPEP, HPN, DNPEP | CTSK 227/4885CTSS 177/4885TGFBR1 4191/4885 |
| US-10150794-B2 | Compounds for enzyme inhibition | ANPEP, HPN, DNPEP | CTSK 227/4885CTSS 177/4885TGFBR1 4191/4885 |
| US-20160083421-A1 | COMPUNDS FOR ENZYME INHIBITION | ANPEP, PSMB1, CPN1 | CTSK 205/4885CTSS 88/4885TGFBR1 3761/4885 |
| US-20090203698-A1 | Compounds for Enzyme Inhibition | ANPEP, HPN, DNPEP | CTSK 227/4885CTSS 177/4885TGFBR1 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.